Influenza A/H3N2/Singapore/GP20238/2024-like virus hemagglutinin, C-terminal T4-foldon-His-tag

Influenza A/H3N2/Singapore/GP20238/2024-like virus hemagglutinin, C-terminal T4-foldon-His-tag

Recombinant Influenza A/H3N2/Singapore/GP20238/2024-like virus hemagglutinin, C-terminal T4-foldon-His-tag purified by metal-affinity and ion exchange chromatography and finalised by dialysis.

PRODUCT DETAILS –Influenza A/H3N2/Singapore/GP20238/2024-like virus hemagglutinin,C-terminal T4-foldon-His-tag 

• Accession: EPI4357487
• Strain/Isolate: H3N2/Singapore/GP20238/2024
• Tag: 6xHis-tag, (C-Terminus)
• Expressed in HEK293
• Presented as liquid in DPBS with high purity by SDS gel

BACKGROUND

Influenza A viruses are negative-sense, single-stranded, segmented RNA viruses classified under the genus Alphainfluenzavirus in the family Orthomyxoviridae (Baldo et al., 2016). They are divided into subtypes based on two surface glycoproteins, haemagglutinin (H1–H18) and neuraminidase (N1–N11) (CDC, 2025; WHO, 2010). In humans, seasonal influenza A viruses predominantly belong to the H1N1 and H3N2 subtypes (CDC, 2025; WHO, 2025).

Seasonal influenza causes substantial global morbidity and mortality, with the World Health Organization estimating around 1 billion infections, 3–5 million severe cases and 290,000–650,000 influenza‑related respiratory deaths each year worldwide. These burdens fall disproportionately on high‑risk groups, including young children, older adults, pregnant women and individuals with chronic underlying conditions. Vaccination remains the primary public‑health intervention to reduce the impact of influenza, supported by WHO‑coordinated global surveillance and strain selection (WHO, 2025).

At The Native Antigen Company, we are committed to advancing vaccine research and development, supporting work on these clinically important influenza A subtypes. We proudly offer Haemagglutinin (HA) and Neuraminidase (NA) antigens for WHO‑recommended egg‑based and recombinant vaccine strains for seasonal influenza, available in bulk quantities for applications including immunoassay development and use as immunogens.

REFERENCES

• • Baldo, V., Bertoncello, C., Cocchio, S. et al. (2016) ‘The new pandemic influenza A/(H1N1)pdm09 virus: Is it really “new”?’, Journal of Preventive Medicine and Hygiene, 57(1), pp. E19–E22.
  • Centers for Disease Control and Prevention (CDC) (2025) Types of Influenza Viruses. Available at: https://www.cdc.gov/flu/about/viruses-types.html (Accessed: 2 February 2026.
  • World Health Organization (WHO) (2010) Virology of Human Influenza. Available at: https://www.who.int/europe/news-room/fact-sheets/item/virology-of-human-influenza (Accessed: 2 February 2026).
  • World Health Organization (WHO) (2025) Influenza (Seasonal) – Fact Sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed: 2 February 2026).